Physician profile
Lucinda Smith
NPI 1023870540
$2,796.52
in general payments reported to CMS, 2019-2025
23 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $803 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,796.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $455.55 | 2024-2025 | Rystiggo, Briviact, Zilbrysq |
| Abbvie INC. | $400.89 | 2024-2025 | |
| Neurelis, INC. | $223.38 | 2024-2025 | Valtoco |
| Lundbeck LLC | $192.90 | 2025 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $171.90 | 2024-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $153.65 | 2024-2025 | Ingrezza |
| Medtronic, INC. | $148.04 | 2024-2025 | Minimed 780g |
| Vanda Pharmaceuticals INC. | $113.44 | 2024 | Fanapt, Hetlioz |
| Sumitomo Pharma America, INC. | $105.80 | 2024-2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $102.43 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $99.28 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.06 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $77.76 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $74.07 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $68.70 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $64.68 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $54.61 | 2025 | |
| Janssen Biotech, INC. | $50.19 | 2025 | |
| Exact Sciences Corporation | $43.59 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $33.69 | 2025 | Auvelity |
| Ardelyx, INC. | $33.03 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $28.00 | 2024 | Voquezna |
| Tg Therapeutics, INC. | $20.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucinda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.